Archives
RCT | Rapid up-titration of guideline-directed medical therapies for acute heart failure reduced readmissions and deaths.
8 Nov, 2022 | 12:24h | UTCSafety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial – The Lancet (free registration required)
News Release: Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death – American Heart Association
Commentary: STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends – TCTMD
Guideline | Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients.
8 Nov, 2022 | 12:21h | UTC
Guideline | Antibiotic prophylaxis for tube thoracostomy placement in trauma.
8 Nov, 2022 | 12:19h | UTC
Review | Management of heart failure with reduced ejection fraction.
8 Nov, 2022 | 12:17h | UTCManagement of heart failure with reduced ejection fraction – Heart
Review | Intravenous fluid therapy in patients with severe acute pancreatitis admitted to the intensive care unit.
8 Nov, 2022 | 12:15h | UTCRelated:
Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis – New England Journal of Medicine (link to abstract – $ for full-text)
Acute Pancreatitis: Diagnosis and Treatment – Drugs
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
RCT | After an out-of-hospital cardiac arrest, fever prevention for 36 vs. 72 hours resulted in similar outcomes.
8 Nov, 2022 | 12:23h | UTCDuration of Device-Based Fever Prevention after Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial involving patients after out-of-hospital cardiac arrest, fever prevention for 36 or 72 hours did not result in different percentages of patients dying or having severe disability or coma. #AHA22 https://t.co/Cx6x4RfqCE pic.twitter.com/vGSb0iVISN
— NEJM (@NEJM) November 6, 2022
RCT | Efficacy of a targeted-release formulation of budesonide for treating primary immunoglobulin A nephropathy.
8 Nov, 2022 | 12:14h | UTCCommentary: Oral Steroid Safely Treats IgA Nephropathy: Trial Published – Medscape (free registration required)
Commentary on Twitter (thread – click for more)
https://twitter.com/hswapnil/status/1582685958881021952
RCT | Precuneus magnetic stimulation for Alzheimer’s disease.
8 Nov, 2022 | 12:12h | UTCPrecuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial – Brain
Commentary: Novel Approach to TMS May Slow Cognitive Decline in Alzheimer’s – Medscape (free registration required)
Commentary on Twitter
In a randomized, double-blind, phase II trial, Koch et al. find that 24 weeks of repetitive transcranial magnetic stimulation of the precuneus slows down cognitive and functional decline in patients with Alzheimer’s disease. https://t.co/jODfVG3GAJ pic.twitter.com/p9ncGTfS7J
— Brain (@Brain1878) October 27, 2022
Single-arm P2 study | Neoadjuvant relatlimab and nivolumab in resectable melanoma.
8 Nov, 2022 | 12:11h | UTCNeoadjuvant relatlimab and nivolumab in resectable melanoma – Nature
News Release: Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma – MD Anderson News Release
Commentary on Twitter
In a phase II trial of neoadjuvant & adjuvant nivolumab+relatlimab in 30 pts with stage III or oligometastatic stage IV melanoma, the pCR rate was 57%, with a 70% pRR; 1- & 2-yr RFS was 100% & 92% vs 88% & 55% for pts with vs without any path. response: https://t.co/2ypNeUTpwb
— NatureRevClinOncol (@NatRevClinOncol) November 1, 2022
Review | Targeted temperature management in postresuscitation care after incorporating results of the TTM2 Trial.
8 Nov, 2022 | 12:09h | UTCRelated:
Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial – Circulation
Hypothermic versus Normothermic Temperature Control after Cardiac Arrest – NEJM Evidence
ERC-ESICM guidelines on temperature control after cardiac arrest in adults – Intensive Care Medicine (if the link is paywalled, try this one)
Cohort Study | Association of obesity with disease outcome in multiple sclerosis.
8 Nov, 2022 | 12:07h | UTCNews Release: Obesity at MS diagnosis linked to higher current and subsequent levels of disability – BMJ
Commentary: Obesity Linked to Greater Disability, Poorer Outcomes in MS – HealthDay
RCT | Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen.
8 Nov, 2022 | 12:06h | UTCEffects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial – Journal of Allergy and Clinical Immunology (link to abstract – $ for full-text)
News Release: Monoclonal antibody improves cat allergen immunotherapy – National Institutes of Health
RCT | Efficacy of an eye-tracking-based dichoptic home treatment for amblyopia.
8 Nov, 2022 | 12:04h | UTC
Review | Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease.
8 Nov, 2022 | 12:02h | UTC
SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.
8 Nov, 2022 | 12:00h | UTC
M-A | Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis.
8 Nov, 2022 | 11:58h | UTC
SR | Pregnancy after living kidney donation.
8 Nov, 2022 | 11:56h | UTCVideo: Pregnancy after living kidney donation, a review of the available evidence and current guidance
Cohort Study | Menstrual cycle regularity and length across the reproductive lifespan and risk of cardiovascular disease.
8 Nov, 2022 | 11:54h | UTCCommentary: Irregular, Long Menstrual Cycles Up Risk for Cardiovascular Disease – HealthDay
Commentary on Twitter
Irregular and long menstrual cycles across a woman’s reproductive lifespan may identify women with a higher risk of cardiovascular disease, even after accounting for established CVD risk factors. #OAResearch #OAWeek https://t.co/BxNveNAqg5
— JAMA Network Open (@JAMANetworkOpen) October 29, 2022
M-A | Outcomes of dexmedetomidine vs. propofol sedation in critically ill adults requiring mechanical ventilation.
8 Nov, 2022 | 11:52h | UTC
Review | Continuous kidney replacement therapy.
8 Nov, 2022 | 11:51h | UTCContinuous KRT: A Contemporary Review – Clinical Journal of the American Society of Nephrology
Review | Radiographic contrast media and the kidney.
8 Nov, 2022 | 11:49h | UTCRadiographic Contrast Media and the Kidney – Clinical Journal of the American Society of Nephrology
CDC Clinical Practice Guideline for prescribing opioids for pain.
7 Nov, 2022 | 13:00h | UTCCommentaries:
CDC issues new opioid prescribing guidance, giving doctors more leeway to treat pain – NPR
SR | Efficacy and safety of IL-6 inhibition with biological DMARDs in immune-mediated inflammatory diseases.
8 Nov, 2022 | 11:47h | UTC
Commentary on Twitter
Check out our latest systematic literature review on IL-6 inhibition in immune-mediated inflammatory diseases:
▶️ positive clinical in a group of diseases
▶️ benefits in #COVID-19
▶️ similar safety outcomes vs other bDMARDs🔗 https://t.co/N1S9H2NrLQ pic.twitter.com/IAFGoEgkrY
— Annals of the Rheumatic Diseases (@eular_ARD) September 29, 2022
NICE Guideline | Self-harm: assessment, management and preventing recurrence.
7 Nov, 2022 | 12:58h | UTC
RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.
7 Nov, 2022 | 12:56h | UTCEmpagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News
Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
Commentary on Twitter
In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx pic.twitter.com/EPU6Rl14F1
— NEJM (@NEJM) November 4, 2022